Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director · President and CEO | February 12, 2024 | February 14, 2024 |
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Director · Chief Executive Officer | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 12, 2024 · Filed February 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 444,867 |
Ending reported balance
After 2024-02-12 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-02-12 · Grant · Acquired 119,000 · Balance 394,000 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Row 2 · 2024-02-12 · Grant · Acquired 179,734 · Balance 573,734 F2: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 179,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Row 3 · 2024-02-12 · Tax withholding · Disposed 47,445 · Balance 526,289 F3: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Row 4 · 2024-02-12 · Tax withholding · Disposed 81,422 · Balance 444,867 F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 179,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.
F3: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.
F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
Indivior Pharmaceuticals, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 790,330 |
Ending reported balance
After 2026-06-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 1,266,903 · Balance 1,402,879 F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-22 · Tax withholding · Disposed 612,549 · Balance 790,330 F3: Shares withheld to satisfy tax withholding obligations associated with the vesting of performance stock units on June 22, 2026. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-22 · Exercise / conversion · Disposed 1,266,903 · Balance 0 F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026.
F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: Shares withheld to satisfy tax withholding obligations associated with the vesting of performance stock units on June 22, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 23, 2026 21:24 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Exercise / conversionPerformance Stock Units · Derivative | 1,266,903 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001443841-26-000007 · wk-form4_1782249862.xml · derivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,266,903 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · price: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. F1 · derivative.expiration_date: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 21:24 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Tax withholdingCommon Stock | 612,549 | $38.32 | $23,472,877.68 |
DisclosureSEC source: 0001443841-26-000007 · wk-form4_1782249862.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 790,330 F3 · shares: Shares withheld to satisfy tax withholding obligations associated with the vesting of performance stock units on June 22, 2026. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 21:24 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Exercise / conversionCommon Stock | 1,266,903 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001443841-26-000007 · wk-form4_1782249862.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,402,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. F2 · price: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:02 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 79,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001443841-26-000004 · wk-form4_1770930173.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,976 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:13 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 81,422 | $33.70 | $2,743,921.40 |
DisclosureSEC source: 0001062993-24-003166 · form4.xml · nonDerivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,867 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:13 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 47,445 | $33.70 | $1,598,896.50 |
DisclosureSEC source: 0001062993-24-003166 · form4.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,289 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:13 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 179,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003166 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 573,734 F2 · shares: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 179,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:13 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003166 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,000 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 21:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 4,357 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001062993-23-023100 · form4.xml · derivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,875 Underlying: Common Stock · 4,357 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. F3 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 21:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,357 | $30.38 | $132,376.55 |
DisclosureSEC source: 0001062993-23-023100 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.13 to $30.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 21:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 4,357 | $21.34 | $92,978.38 |
DisclosureSEC source: 0001062993-23-023100 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 279,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. Read SEC document |
| December 20, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 26,454 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · derivative · entry 9 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,232 Underlying: Common Stock · 26,454 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. F5 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| December 20, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 26,454 | $30.40 | $804,209.54 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · nonDerivative · entry 6 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.64, inclusive. Read SEC document |
| December 20, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 26,454 | $21.34 | $564,528.36 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · nonDerivative · entry 5 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 14,516 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · derivative · entry 8 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,686 Underlying: Common Stock · 14,516 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. F5 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 14,516 | $30.03 | $435,941.61 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · nonDerivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.185, inclusive. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 14,516 | $21.34 | $309,771.44 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 27,798 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · derivative · entry 7 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,202 Underlying: Common Stock · 27,798 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. F5 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 27,798 | $30.04 | $834,935.17 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:51 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 27,798 | $21.34 | $593,209.32 |
DisclosureSEC source: 0001062993-23-022977 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 23:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,000 | $22.25 | $22,251.10 |
DisclosureSEC source: 0001062993-23-012809 · form4.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.09 to $22.39, inclusive. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 23:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 30,272 | $21.58 | $653,172.89 |
DisclosureSEC source: 0001062993-23-012809 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.09 to $22.085, inclusive. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 23:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 31,272 | $22.09 | $690,757.83 |
DisclosureSEC source: 0001062993-23-012809 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,272 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.81 to $22.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 31,272 | $21.87 | $683,796.68 |
DisclosureSEC source: 0001062993-23-012623 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,544 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.62 to $22.22, inclusive. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 31,271 | $21.90 | $684,906.82 |
DisclosureSEC source: 0001062993-23-012623 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 368,816 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.62 to $22.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 11,250 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001062993-23-003475 · form4.xml · derivative · entry 7 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, initially representing a right to purchase a total of 90,00 shares, is fully vested and exercisable. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 11,250 | $26.88 | $302,400.00 |
DisclosureSEC source: 0001062993-23-003475 · form4.xml · nonDerivative · entry 6 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,087 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.485 to $27.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 11,250 | $15.90 | $178,875.00 |
DisclosureSEC source: 0001062993-23-003475 · form4.xml · nonDerivative · entry 5 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 59,736 | $26.75 | $1,597,938.00 |
DisclosureSEC source: 0001062993-23-003475 · form4.xml · nonDerivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,087 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 44,121 | $26.75 | $1,180,236.75 |
DisclosureSEC source: 0001062993-23-003475 · form4.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,823 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 137,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-003475 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,944 F2 · price: Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 137,694 performance share units granted in the issuer's three prior fiscal years. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 117,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-003475 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,250 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 00:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 400 | $24.19 | $9,676.00 |
DisclosureSEC source: 0001062993-22-024500 · form4.xml · nonDerivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,750 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.14 to $24.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4). Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 00:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,804 | $23.65 | $42,664.60 |
DisclosureSEC source: 0001062993-22-024500 · form4.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3). Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 00:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 147 | $23.00 | $3,381.00 |
DisclosureSEC source: 0001062993-22-024500 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2). Read SEC document |
| December 22, 2022 Filed Dec 28, 2022 00:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 110 | $23.00 | $2,530.00 |
DisclosureSEC source: 0001062993-22-024500 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,101 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 7,333 | $23.11 | $169,465.63 |
DisclosureSEC source: 0001062993-22-024355 · form4.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,211 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4). Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 9,375 | $23.07 | $216,281.25 |
DisclosureSEC source: 0001062993-22-024355 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,544 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3). Read SEC document |
| December 19, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,134 | $23.01 | $26,093.34 |
DisclosureSEC source: 0001062993-22-024355 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,919 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2). Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 23:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 54,400 | $23.07 | $1,255,008.00 |
DisclosureSEC source: 0001062993-22-023357 · form4.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,053 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.26, inclusive. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 23:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 76,653 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001062993-22-023357 · form4.xml · derivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,653 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the 76,653 option shares are exercisable. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 23:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 76,653 | $22.47 | $1,722,392.91 |
DisclosureSEC source: 0001062993-22-023357 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,453 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 23:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 76,653 | $15.90 | $1,218,782.70 |
DisclosureSEC source: 0001062993-22-023357 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 22:59 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 43 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001062993-22-022995 · form4.xml · derivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the 43 option shares are exercisable. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 22:59 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 43 | $22.00 | $946.00 |
DisclosureSEC source: 0001062993-22-022995 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,453 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 22:59 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 43 | $15.90 | $683.70 |
DisclosureSEC source: 0001062993-22-022995 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 23:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 65 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001062993-22-022779 · form4.xml · derivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the 65 option shares are exercisable. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 23:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 65 | $22.00 | $1,430.00 |
DisclosureSEC source: 0001062993-22-022779 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,453 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 23:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 65 | $15.90 | $1,033.50 |
DisclosureSEC source: 0001062993-22-022779 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:44 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 1,989 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001062993-22-022644 · form4.xml · derivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,989 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the 1,989 option shares are exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.